Recent Advances in the Treatment of Sickle Cell Anemia

  • Ahmed Al-Salem


Sickle cell anemia is one of the common hemoglobinopathies around the world.


Blood Transfusion Sickle Cell Anemia Sickle Cell Trait Sickle Cell Anemia Patient Fetal Hemoglobin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Further Reading

  1. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5–11.CrossRefPubMedGoogle Scholar
  2. Brittenham GW, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol. 1993;42:81–5.CrossRefPubMedGoogle Scholar
  3. Cox JV, Steane E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med. 1988;148:2485–9.CrossRefPubMedGoogle Scholar
  4. Emre U, Miller ST, Gutierez M, Steiner P, Rao SP, Rao M. Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr. 1995;127:901–4.CrossRefPubMedGoogle Scholar
  5. Hasan MF, Marsh F, Posner G, et al. Chronic hepatitis C in patients with sickle cell disease. Am J Gastroenterol. 1996;91:1204–6.PubMedGoogle Scholar
  6. Kim HC, Dugan NP, Silber JH, Martin MB, Schwartz E, Ohene-Frempong K, Cohen AR. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood. 1994;83:1136–42.PubMedGoogle Scholar
  7. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood. 1990;76:1431–7.PubMedGoogle Scholar
  8. Silliman CC, Peterson VM, Mellman DL, Dixon DJ, Hambidge KM, Lane PA. Iron chelation by desferrioxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. J Lab Clin Med. 1993;122:48–54.PubMedGoogle Scholar
  9. Singer ST, Quirolo K, Nishi K, Hackney-Stephens E, Vichinsky E. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apher. 1999;14:122–5.CrossRefPubMedGoogle Scholar
  10. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med. 1995;333:206–13.CrossRefPubMedGoogle Scholar
  11. Wang WC, Kovnar EH, Tonkin IL, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 1991;81:1109–23.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Ahmed Al-Salem
    • 1
  1. 1.Department of SurgeryDar A lAlafia Medical CompanyQatifSaudi Arabia

Personalised recommendations